

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines Powder for injection: 10 000 IU in vial. Parenteral > General injections > unspecified: 10000 IU in vial powder for injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15 mg in vial (as sulfate) Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified malignant neoplasms of the ovary Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma

Calcium folinate (leucovorin calcium)

Section	Indications
Cytotoxic medicines Oral > Solid: 15 mg tablet Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule Oral > Solid > tablet: 15 mg; 5 mg; 25 mg	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasm metastasis in large intestine Malignant trophoblastic neoplasms of placenta Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of rectum Malignant neoplasms of colon Osteosarcoma of bone and articular cartilage of unspecified sites

Capecitabine

Section	Indications
Cytotoxic medicines Oral > Solid: 150 mg tablet; 500 mg tablet	Malignant neoplasms of colon Other specified malignant neoplasms of breast Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum

Carboplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL	Other specified gliomas of brain Osteosarcoma of bone and articular cartilage of unspecified sites Other specified carcinomas of ovary Retinoblastoma Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Malignant neoplasms of kidney, except renal pelvis Malignant neoplasms of breast Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri Other specified malignant neoplasms of the ovary Germ cell tumour of testis

Chlorambucil

Section

Cytotoxic medicines

Oral > Solid: 2 mg tablet

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cisplatin

Section

Cytotoxic medicines

Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection

Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Malignant neoplasms of nasopharynx

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Germ cell tumour of testis

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of lip, oral cavity or pharynx

Cladribine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

Langerhans cell histiocytosis

Cyclophosphamide

Section	Indications
Cytotoxic medicines Oral > Solid: 25 mg tablet Parenteral > General injections > unspecified: 500 mg in vial powder for injection Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Oral > Solid: 25 mg; 50 mg Oral > Solid: 25 mg; 50 mg tablet	- Unspecified malignant neoplasms of ill-defined or unspecified sites - Other specified gliomas of brain - Plasma cell myeloma - Other specified malignant neoplasms of breast - Malignant neoplasms of kidney, except renal pelvis - Rhabdomyosarcoma primary site - Malignant trophoblastic neoplasms of placenta - Follicular lymphoma - Burkitt lymphoma including Burkitt leukaemia - Malignant neoplasms of breast - Ewing sarcoma of bone and articular cartilage of unspecified sites - Lymphoid leukaemia, not elsewhere classified - Chronic lymphocytic leukaemia or small lymphocytic lymphoma - Diffuse large B-cell lymphomas - Hodgkin lymphoma - Anaplastic large cell lymphoma, ALK-positive - Anaplastic large cell lymphoma, ALK-negative

Cytarabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 100 mg in vial powder for injection Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial	- Unspecified malignant neoplasms of ill-defined or unspecified sites - Acute myeloid leukaemia with recurrent genetic abnormalities - Burkitt lymphoma including Burkitt leukaemia - Lymphoid leukaemia, not elsewhere classified - Myeloid leukaemia - Langerhans cell histiocytosis - Anaplastic large cell lymphoma, ALK-negative - Anaplastic large cell lymphoma, ALK-positive

Dacarbazine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

Hodgkin lymphoma

Dactinomycin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Ewing sarcoma of bone and articular cartilage of unspecified sites

Daunorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Docetaxel

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Other specified malignant neoplasms of breast

Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride); 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Parenteral > General injections > IV: 50 mg in vial (hydrochloride) +; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride); 10 mg in vial (hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of breast

Other specified malignant neoplasms of breast

Diffuse large B-cell lymphomas

Plasma cell myeloma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Lymphoid leukaemia, not elsewhere classified

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Doxorubicin (as pegylated liposomal)

Section

Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

Kaposi sarcoma of unspecified primary site

Etoposide

Section

Cytotoxic medicines

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule

Oral > Solid: 100 mg capsule

Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)

Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant trophoblastic neoplasms of placenta

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Hodgkin lymphoma

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Fludarabine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule Parenteral > General injections > IV: 50 mg per mL in vial	Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of nasopharynx Malignant neoplasm metastasis in large intestine Malignant neoplasms of rectum Malignant neoplasms of breast Malignant neoplasms of colon

Gemcitabine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified carcinomas of ovary Other specified malignant neoplasms of bronchus or lung

Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	Squamous cell carcinoma of oropharynx Chronic myeloid leukaemia, not elsewhere classified

Ifosfamide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection	Other specified malignant neoplasms of the ovary Germ cell tumour of testis Ewing sarcoma of bone and articular cartilage of unspecified sites Osteosarcoma of bone and articular cartilage of unspecified sites Rhabdomyosarcoma primary site Unspecified malignant neoplasms of ill-defined or unspecified sites Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of kidney, except renal pelvis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Irinotecan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site

Melphalan

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection Oral > Solid: 2 mg	Plasma cell myeloma

Mercaptopurine

Section	Indications
Cytotoxic medicines Oral > Solid: 50 mg tablet Oral > Liquid: 20 mg per mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis

Methotrexate

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as sodium salt) Oral > Solid: 2.5 mg (as sodium salt) Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Acute myeloid leukaemia with recurrent genetic abnormalities Burkitt lymphoma including Burkitt leukaemia Malignant neoplasms of breast Lymphoid leukaemia, not elsewhere classified Malignant trophoblastic neoplasms of placenta Osteosarcoma of bone and articular cartilage of unspecified sites Langerhans cell histiocytosis Anaplastic large cell lymphoma, ALK-negative Anaplastic large cell lymphoma, ALK-positive

Oxaliplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial	Malignant neoplasm metastasis in large intestine Malignant neoplasms of colon

Paclitaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 6 mg per mL	Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Kaposi sarcoma of unspecified primary site Other specified malignant neoplasms of breast Other specified carcinomas of ovary Malignant neoplasms of breast Malignant neoplasms of cervix uteri

Pegaspargase

Section

Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

Lymphoid leukaemia, not elsewhere classified

Procarbazine

Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section

Cytotoxic medicines

Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

Tioguanine

Section

Cytotoxic medicines

Oral > Solid: 40 mg

Indications

Lymphoid leukaemia, not elsewhere classified

Vinblastine

Section

Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)

Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified gliomas of brain

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Kaposi sarcoma of unspecified primary site

Hodgkin lymphoma

Langerhans cell histiocytosis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Vincristine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate) Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Malignant trophoblastic neoplasms of placenta Follicular lymphoma Malignant neoplasms of kidney, except renal pelvis Ewing sarcoma of bone and articular cartilage of unspecified sites Kaposi sarcoma of unspecified primary site Rhabdomyosarcoma primary site Hodgkin lymphoma Diffuse large B-cell lymphomas Retinoblastoma Burkitt lymphoma including Burkitt leukaemia Lymphoid leukaemia, not elsewhere classified Langerhans cell histiocytosis

Vinorelbine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 50 mg per 5 mL in 5 mL vial Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial Oral > Solid: 20 mg; 30 mg; 80 mg	Other specified malignant neoplasms of bronchus or lung Other specified malignant neoplasms of breast Rhabdomyosarcoma primary site